US2013109719A1PendingUtilityA1

Method of treating attention deficit disorders with d-threo methylphenidate

67
Individually held — no corporate assignee on recordPriority: Dec 4, 1995Filed: Dec 20, 2012Published: May 2, 2013
Est. expiryDec 4, 2015(expired)· nominal 20-yr term from priority
Inventors:Andrew ZeitlinMaghsoud M. DarianiDavid L. Stirling
C12P 41/006A61K 31/4458A61K 31/445A61K 9/2886A61K 9/5084C07D 211/34C12P 17/12A61K 9/5078A61P 25/28A61K 9/1676A61P 25/00
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method of treating Attention Deficit Hyperactivity Disorder comprising administrating on a daily basis to a human having Attention Deficit Hyperactivity Disorder, 5 to 50 mg of D-threo methylphenidate, or a pharmaceutically acceptable salt thereof, substantially free of L-threo methylphenidate, wherein the D-threo methylphenidate, or pharmaceutically acceptable salt, is mixed with a pharmaceutically acceptable carrier, diluent, or excipient. 
     
     
         2 . The method according to  claim 1  wherein the amount of D-threo methylphenidate administered is 5 mg per day. 
     
     
         3 . The method according to  claim 1  wherein the amount of said D-threo methylphenidate, or a pharmaceutically equivalent salt thereof, is greater than 90% of the total amount of methylphenidate. 
     
     
         4 . The method according to  claim 4  wherein the amount of said D-threo methylphenidate, or a pharmaceutically equivalent salt thereof, is greater than 99% of the total amount of methylphenidate. 
     
     
         5 . The method according to  claim 1  wherein the amount of D-threo methylphenidate enhances therapeutic activity compared to racemic methylphenidate. 
     
     
         6 . The method according to  claim 1  wherein the administration is one to four times per day. 
     
     
         7 . The method according to  claim 1  wherein the amount of D-threo methylphenidate administered is 20 mg per day. 
     
     
         8 . The method according to  claim 1  wherein the amount of D-threo methylphenidate administered is 50 mg per day.

Join the waitlist — get patent alerts

Track US2013109719A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.